Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
Authors:
Open Access
- 26 September 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (1) , 54-62
Abstract
Background PF‐04965842 is an oral Janus kinase 1 inhibitor being investigated for the treatment of plaque psoriasis. Objectives To evaluate the efficacy, safety and tolerability of PF‐04965842 in patients with moderate‐to‐severe plaque psoriasis. Methods Patients in this phase II, placebo‐controlled study (NCT02201524) were randomized to receive placebo, 200 mg once daily (OD), 400 mg OD or 200 mg twice daily (TD) PF‐04965842 for 4 weeks. The primary endpoint was change from baseline in Psoriasis Area Severity Index (PASI) at week 4. Study enrolment was discontinued on 25 June 2015 due to changes in the sponsor's development priorities. Results Fifty‐nine patients were randomized and received at least one dose of PF‐04965842 or placebo. The estimated treatment effect (active –placebo PASI change from baseline) and 90% confidence interval at week 4 was −5·1 (−9·2 to −1·0), −5·6 (−9·6 to −1·6) and −10·0 (−14·2 to −5·8) for the 200 mg OD, 400 mg OD and 200 mg TD groups, respectively. At week 4, the proportion of patients achieving PASI 75 was 17% for the placebo and 200 mg OD groups, 50% for the 400 mg OD group and 60% for the 200 mg TD group. There were more abnormal laboratory test results of clinical interest (low neutrophil, reticulocyte and platelet counts) in the 200 mg TD group compared with the OD treatment groups. No serious infections or bleeding events related to neutropenia or thrombocytopenia, respectively, were reported. Conclusions These results suggest that treatment with PF‐04965842 improves symptoms and is well tolerated in patients with moderate‐to‐severe psoriasis.Keywords
Funding Information
- Pfizer
This publication has 20 references indexed in Scilit:
- Jakpot! New small molecules in autoimmune and inflammatory diseasesExperimental Dermatology, 2013
- Janus kinase inhibitors in autoimmune diseasesAnnals of the Rheumatic Diseases, 2013
- Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapiesJournal of the European Academy of Dermatology and Venereology, 2013
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- JAKs and STATs in Immunity, Immunodeficiency, and CancerNew England Journal of Medicine, 2013
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseCurrent Opinion in Pharmacology, 2012
- On Efficiency of Constrained Longitudinal Data Analysis Versus Longitudinal Analysis of CovarianceBiometrics, 2009
- PsoriasisNew England Journal of Medicine, 2009
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978